Acute Myocardial Infarction in Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Surviving Case

Ade Ajeng Cempakadewi,1 Putu Ayu Diah Puspita Sari,1,2 I Putu Gede Budiana2

1Department of Pulmonology and Respiratory Medicine, Mangusada Regional General Hospital, Bali, Indonesia
2Department of Cardiology and Vascular Medicine, Mangusada Regional General Hospital, Bali, Indonesia

Abstract

Background: COPD is characterized by chronic respiratory symptoms with progressive, irreversible structural abnormalities and impaired lung function. Previously, COPD was known as a condition that only affected the airways and lungs, but recent studies have revealed the incidence of cardiovascular disease in this population as the prevalence increased.

Case: A 68-year-old male came to the emergency room fully conscious, complaining of shortness of breath since the afternoon. A physical examination detected tachypnea, desaturation of oxygen, and additional breath sounds in both lungs. Blood gas analysis with the result of respiratory acidosis supported the diagnosis of AECOPD (acute exacerbations of chronic obstructive pulmonary disease), impending type II respiratory failure, cor-pulmonale. During the treatment in the intensive unit, the physicians recognized deteriorating conditions as unconsciousness, unstable vital signs, and ST-T segment changes on the ECG with an elevated cardiac marker. Other medications (antiplatelet, LMWH, and statin) were given immediately. The patient’s condition improved. On the ninth day of the treatments, the patient was discharged home.

Discussion: Acute exacerbations of COPD have a higher risk of developing ischemic heart disease with varying underlying mechanisms (atherosclerosis process and oxygen supply-demand imbalance). Understanding the numerous pathways that contribute to AMI (acute myocardial infarction) in COPD will help physicians determine the therapy.

Conclusion: Based on this case, the ECG and cardiac enzymes warrant immediate evaluation, as must symptoms, vital signs, clinical findings, and other changes. Delays in case finding and treatment can worsen the prognosis.

Keywords: AECOPD, AMI, atherosclerosis, hypoxia, respiration

INTRODUCTION

COPD is characterized by chronic respiratory symptoms, progressive and irreversible structural abnormalities, and impaired lung function. Previously, COPD was known as a condition that only affected the airways and lungs, but recent studies have revealed the incidence of cardiovascular disease in this population as prevalence increased.1

Various processes might contribute to the association between COPD and ischemic heart disease. There are similarities in the risk factor profile between the same degree of smoking habits and elderly age, as well as increased secretion of pro-inflammatory cytokines. Exacerbation inflammation is not restricted to the airways but composes a systemic inflammatory process. Platelet activation and enhanced thrombotic processes are all present in AECOPD. Those affect the formation of atherosclerosis.1,2

Besides that process, ischemic heart disease in people with COPD is more common due to hypoxia. The incidence of acute myocardial infarction not only exists in acute exacerbations of COPD patients but also in moderate-grade stable COPD conditions and cardiovascular comorbidities.3

There are 30% of COPD deaths due to cardiovascular problems. Because of unspecified signs, acute myocardial infarction (AMI) is rarely detected in acute exacerbations of COPD (AECOPD) patients, resulting in diagnosis delays and treatment.1,3 The existence of a close relationship between COPD and the risk of acute myocardial infarction and death, therefore, requires appropriate identification, evaluation, and treatment.1

Complementary 12-lead electrocardiography (ECG), transthoracic echocardiography, pulmonary
function tests, laboratory parameters for inflammation and myocardial injury, and also coronary computed tomography angiography (CCTA) have been used to evaluate impaired cardiac function in COPD patients in the absence of specific cardiac disease.

Therefore, this case report aimed to give an example of rapid diagnosis and comprehensive treatment of AMI in AECOPD, showing a specific outcome for the patient’s condition, including saving the patients’ lives.

CASE

A 68-year-old male came to the emergency room fully conscious, complaining of shortness of breath since the afternoon. Patients frequently experience breathing difficulties, especially on long walks or strenuous activities. Breathing difficulties decrease with rest. The patient denied any other symptoms, such as cough, fever, chest pain, and partial weakness on one side of the body. There was no complaints with appetite, urination or defecation.

The patient previously took several medications, such as salmeterol xinafoate 50 µg combined with fluticasone propionate 250 µg, orally furosemide 20 mg, carvedilol 6.25 mg, and candesartan 8 mg, as part of his medication history. However, the medicines were only sometimes obtained and consumed. On physical assessment in the emergency room, the consciousness level was E4V5M6, blood pressure was 102/71 mmHg, heart rate was 70 times per minute regularly, respiratory rate was 28 times per minute, oxygen saturation of 89% (SpO₂) evaluated by pulse oximetry, and temperature was 36 degrees Celsius. A physical examination of the thorax detected additional breath sounds (rhonchi and wheezing) in both lungs. The other organ evaluation results were within normal limits.

The initial therapy was administered immediately, with ten drops per minute of normal saline and oxygen supplementation through a non-rebreathing mask (NRM) of 10 liters per minute. Additionally, blood samples were collected for complete blood count examinations, blood chemistry evaluations (random blood sugar, kidney function tests, liver function tests, electrolytes, and lactic acid), and blood gas analysis. Electrocardiography and chest X-rays (CXR) were also performed (Figure 1, Table 1).

The initial patient’s ECG showed left ventricle hypertrophy with left axis deviation and an old myocardial infarction on the inferior lead (II, III, and aVF leads). The complete blood test revealed an increase in absolute neutrophil count followed by an elevation of NLR and decreased kidney function, which was marked by a slight increase in blood urea nitrogen-serum creatinine levels. The blood gas study revealed a decline in pH, an elevation in pCO₂, and an increase in HCO₃⁻. The level of oxygen remains normal at 100%. The arterial blood gas was examined after patients had oxygen supplementation by a NRM at ten liters per minute.

The initial patient’s ECG showed left ventricle hypertrophy with left axis deviation and an old myocardial infarction on the inferior lead (II, III, and aVF leads). The complete blood test revealed an increase in absolute neutrophil count followed by an elevation of NLR and decreased kidney function, which was marked by a slight increase in blood urea nitrogen-serum creatinine levels. The blood gas study revealed a decline in pH, an elevation in pCO₂, and an increase in HCO₃⁻. The level of oxygen remains normal at 100%. The arterial blood gas was examined after patients had oxygen supplementation by a NRM at ten liters per minute.

Based on history, physical examination, and laboratory findings, the diagnosis came with an acute exacerbation of COPD, respiratory acidosis, impending type II respiratory failure, and a suspected cor-pulmonale.
Table 1. Blood chemistry and blood gas analysis

<table>
<thead>
<tr>
<th>Indicator</th>
<th>18/02/2023</th>
<th>22/02/2023</th>
<th>25/02/2023</th>
<th>Reference interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood chemistry test</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Random blood sugar</td>
<td>201</td>
<td>---</td>
<td>---</td>
<td>70-140 mg/dL</td>
</tr>
<tr>
<td>SGOT</td>
<td>23</td>
<td>---</td>
<td>---</td>
<td>11-33 U/L</td>
</tr>
<tr>
<td>SGPT</td>
<td>12</td>
<td>---</td>
<td>---</td>
<td>11-50 U/L</td>
</tr>
<tr>
<td>Ureum</td>
<td>62^</td>
<td>---</td>
<td>76^</td>
<td>15-45 mg/dL</td>
</tr>
<tr>
<td>Creatinin</td>
<td>1.9^</td>
<td>---</td>
<td>1.4^</td>
<td>0.70-1.20 mg/dL</td>
</tr>
<tr>
<td>eGFR</td>
<td>35</td>
<td>---</td>
<td>51</td>
<td>mL/min/1.73 m 2</td>
</tr>
<tr>
<td>Na</td>
<td>141</td>
<td>---</td>
<td>---</td>
<td>136-145 mmol/L</td>
</tr>
<tr>
<td>K</td>
<td>4.5</td>
<td>---</td>
<td>---</td>
<td>3.5-5.1 mmol/L</td>
</tr>
<tr>
<td>CI</td>
<td>108</td>
<td>---</td>
<td>---</td>
<td>94-110 mmol/L</td>
</tr>
<tr>
<td>Blood gas analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactic acid</td>
<td>1.12</td>
<td>0.97</td>
<td>---</td>
<td>0.36-1.25 mmol/L</td>
</tr>
<tr>
<td>pH</td>
<td>7.262^*</td>
<td>7.413</td>
<td>---</td>
<td>7.35-7.45</td>
</tr>
<tr>
<td>pCO₂</td>
<td>79.7^</td>
<td>64.1^</td>
<td>---</td>
<td>35-45 mmHg</td>
</tr>
<tr>
<td>pO₂</td>
<td>321^</td>
<td>176^</td>
<td>---</td>
<td>80-100 mmHg</td>
</tr>
<tr>
<td>BE ecf</td>
<td>9^</td>
<td>16^</td>
<td>---</td>
<td>(-2) – (+2) mmol/L</td>
</tr>
<tr>
<td>HCO₃</td>
<td>35.9^</td>
<td>40.9^</td>
<td>---</td>
<td>23-26 mmol/L</td>
</tr>
<tr>
<td>CO₂ total</td>
<td>38.0^</td>
<td>43^</td>
<td>---</td>
<td>24-30 mmol/L</td>
</tr>
<tr>
<td>SaO₂</td>
<td>100</td>
<td>100</td>
<td>---</td>
<td>95-99%</td>
</tr>
</tbody>
</table>

Notes: ^above normal; *below normal

Cor-pulmonale was diagnosed with a history of chronic obstructive pulmonary disease, which is the most common cause of this condition. The physician didn’t perform echocardiography to assess the right ventricle (RV) function because the patient was still unstable.

Oxygenation therapy via NRM at ten liters per minute was continued, with normal saline at eight drops per minute as fluid resuscitation. In addition to the fluid and oxygen resuscitation in stabilization phases, patients received hydrocortisone 100 mg intravenously every 12 hours, cetirizine 10 mg every 12 hours orally, salbutamol + ipratropium bromide and budesonide nebulization every 12 hours, and pursed lip breathing exercises every hour for 10 minutes from the pulmonologist. Meanwhile, the patient also had diuretic therapy using furosemide 20 mg intravenously every 8 hours and spironolactone 25 mg every 24 hours from the cardiologist. The patient was treated in the high-care unit (HCU) for close observation and further treatment.

After three days of treatment at the HCU, the patient experienced a wet cough and fever. Sputum was thick and yellowish-white. Physical examination indicated unstable condition, where blood pressure was 83/46 mmHg, heart rate was tachycardia of 137 beats per minute, respiratory rate was 16 times per minute, SpO2 of 98% with an NRM of 8 liters per minute, and a temperature of 39.1 degrees Celsius. The patient went into shock and did not respond to fluid resuscitation. Further investigations were made to find the cause of the decline in the condition. There were ST segment changes on the ECG and increased cardiac enzymes. The ECG revealed T inversion on inferior lead (II, III, aVF), which was indicative of ischemic. The elevated WBC from 8.840 to 11.680 indicated a bacterial infection from the respiratory system. The evaluation of BGA (blood gas analysis) showed a slight restoration of pH and a decrease in pCO₂.

A vasopressor was given to a patient, starting from the lowest dose of 0.05 µg/kgBW/minute until titrated to a target MAP of 65 mmHg. Fluids were maintained with an infusion pump of 50 cc/hour. The patient received antibiotic therapy with a suspected hospital-acquired pneumonia (HAP), septic shock or cardiogenic shock. Additionally, Moxifloxacin 400 mg every 24 hours and Cefoperazone 1 gram every 12 hours were administered intravenously, along with Paracetamol 1 gram every 8 hours as antipyretics.
Table 2. Lipid profile, cardiac marker, uric acid examination

<table>
<thead>
<tr>
<th>Indicator</th>
<th>23/02/2023</th>
<th>24/02/2023</th>
<th>Reference interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Troponin - I</td>
<td>95.5^</td>
<td>90.2^</td>
<td>&lt;19 ng/L</td>
</tr>
<tr>
<td>CKMB</td>
<td>16.6</td>
<td>28.1^</td>
<td>≤25 U/L</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>125</td>
<td>---</td>
<td>&lt;200 mg/dL</td>
</tr>
<tr>
<td>HDL</td>
<td>22^</td>
<td>---</td>
<td>35-60 mg/dL</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>103</td>
<td>---</td>
<td>&lt;150 mg/dL</td>
</tr>
<tr>
<td>LDL</td>
<td>82</td>
<td>---</td>
<td>&lt;130 mg/dL</td>
</tr>
<tr>
<td>Uric acid</td>
<td>4.2</td>
<td>---</td>
<td>2.0-7.0 mg/dL</td>
</tr>
</tbody>
</table>

Notes: ^above normal; *below normal

We also gave oral N-Acetylcysteine 200 mg every 8 hours and salbutamol 2 mg every 12 hours. The shock continued to degrade the patient’s condition on the fifth day of treatment. Decreased consciousness was shown with GCS of E2V4M5 and being uncooperative on examination. Evaluation of the ECG still found inferior ischemia and increased cardiac enzymes (Table 2). An additional diagnosis of NSTEMI was established, with adjuvant therapy of Clopidogrel 75 mg, Acetosal 80 mg, Atorvastatin 40 mg, and LMWH 0.4 cc being administered every 24 hours.

The patient’s condition improved in the seven days of hospitalization after being given the ACS (acute coronary syndrome) medication. Vital signs were stable, so the patient was transferred to the regular treatment room. The patient was permitted to return home on the ninth day of treatment.

Figure 2. Patient’s ECG, (a). 1st ECG in the ER (18/02/2023) Left ventricle hypertrophy with left axis deviation and old myocardial infarction on II, III, aVF lead; (b). ECG in the intensive unit (23/02/2023) ST-T changes (T inversion) on inferior lead, signed of inferior ischemia

Figure 3. Patients’ timeline

Figure 3. Patients’ timeline
DISCUSSION

Cardiovascular disease is the most common comorbidity found in COPD patients. In most patients, the cause of death in COPD patients is the underlying cardiovascular disease rather than the respiratory problems. Acute myocardial infarction in COPD patients occurs through various mechanisms, but the precise mechanism is not entirely defined. It is probably derived from two pathogenic causes: acute coronary thrombosis due to a systemic inflammatory reaction and also a mismatch between myocardial demand and oxygen supply. The existence of common risk factors like smoking, sedentary behavior, and elderly age are the essential things that must be discovered.

In COPD, a systemic inflammatory process is characterized by an increase in pro-inflammatory proteins and cytokines in the acute phase, such as interleukin-6 and interleukin-18. Platelet reactivation is also triggered and increases the risk of thrombosis. The finding of blood vessels that are more rigid in exacerbation conditions by examining the carotid-femoral aortic pulse wave velocity (aPWV) indicates endothelial dysfunction. These factors all enhance the possibility of AMI.

Besides the atherosclerosis process, a study from McAllister, cited in Goedemans et al, stated that the highest incidence of myocardial infarction in COPD patients was due to the mechanism of oxygen supply-demand imbalance. The imbalance between these two mechanisms is part of the pathophysiology of type 2 myocardial infarction (T2MI). T2MI happens depending on numerous determinants, such as tension on the systolic wall, contractility, heart rate, and myocardial oxygen supply that relies on the coronary blood flow and oxygen-carrying capacity.

Acute hypoxemic condition in COPD exacerbations is an example of this situation. It can stimulate sympathetic nervous system activity through arterial chemoreceptor stimulation. This sympathetic stimulation will lead to tachycardia and the risk of ischemic heart disease. It could cause myocardial cell death, symptoms, abnormalities in the ECG, and also the release of cTn (cardiac troponin). COPD-related hypoxia is also associated with activation of the renin-angiotensin system, which causes decreased renal blood flow, peripheral vasoconstriction, and increased oxidative stress, ultimately increasing the risk of acute myocardial infarction.

Acute exacerbation episodes in COPD patients are enforced based on the fulfilled indicators of the cardinal symptoms, including an increase in dyspnea, sputum quantity, and sputum purulence. During the treatment period, a spirometry examination could not be performed because the patient was still in a hemodynamically unstable condition with findings of myocardial infarction, which is a contraindication to this examination. As a result, the severity of exacerbations is determined based on clinical findings and patient support where there is a risk of life-threatening respiratory failure.

Myocardial infarction is rarely detected in hospitalized AECOPD patients. Based on clinical manifestations, patients with AMI in COPD had a slight possibility of typical chest pain complaints. Patients mostly report unusual chest pain, along with palpitations and shortness of breath. Similar to this case, the patients didn’t feel anything despite a decrease in consciousness. In addition to atypical clinical symptoms, overlapping symptoms make finding cardiac problems in AECOPD more challenging than in regular patients. Patients are more likely to have NSTEMI than STEMI and lower cardiac enzymes (troponin and creatinine kinase) values in further studies.

The pathological picture on the ECG might describe a transient secondary ischemic condition triggered by an increase in oxygen demand, while the oxygen supply is reduced and insufficient to fulfill those demands. If ischemic heart disease is suspected, echocardiography may be adjusted to assess ventricular function and identify the location of vascular occlusion. In conditions of exacerbation, this examination is challenging to perform due to the limited acoustic window. Cardiac MRI can be chosen as an alternative in these conditions.
markers such as troponin-T, troponin-I, and brain natriuretic peptide (BNP) are additional tests to be selected. However, troponin measurement is not specific to ischemic cases because this cardiac enzyme can increase in conditions of heart failure, renal dysfunction, pulmonary embolism, pulmonary hypertension, tachyarrhythmia, and sepsis.  

Coronary angiography would evaluate problems inside the coronary arteries with a transfemoral or transradial approach. This test evaluates atherosclerotic processes, arterial stiffness, and coronary stenosis ≥50%, which may be a reliable indicator of cardiovascular issues. According to a study from Pizarro et al, among 88 patients with AECOPD and increased cardiac troponin who underwent the prospective cohort research, 38.6% had angiographically confirmed ischemic heart disease that required revascularization PCI (percutaneous coronary intervention). The operator’s expertise and standard procedures determined the interventional method for each patient.

Compared to the non-COPD group, invasive therapy (percutaneous coronary intervention) for AMI in COPD patients is rarely given. The decision-making process’s factors may not be completely understood. However, the age aspect, where COPD patients typically manifest in the elderly with a high vulnerability, may be taken into consideration. Several medications are suggested to prevent cardiovascular problems after MI in COPD, including β-blockers, dual anti-platelets (aspirin and P2Y12 receptor antagonists, given for a year), statins, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. β-blockers should not be used in patients with COPD because of the possibility of bronchospasm. However, many studies have shown that cardio-selective β-blockers that are primarily active at cardiac β1 receptors, not bronchial β2 receptors, are not associated with changes in FEV1 or increased COPD exacerbations.

The danger of acute myocardial infarction in COPD is not only feared to occur in critical conditions but can also occur in the advanced phase. It was reported in several studies cited in the study of Goedemans et al that the outcome of AMI conditions in COPD patients requires special attention because it can cause heart failure, arrhythmias, and death. No proof exists that COPD patients with AMI are more likely than non-COPD patients to experience significant bleeding, stroke, or recurrent AMI.

Based on the IRR (incidence rate ratio) and 95% CI (95% confidence interval), it has been concluded that severe airflow limitations in AECOPD (GOLD 3-4) have a stronger association with myocardial infarction compared to mild-to-moderate (GOLD 1-2). The more severe AECOPD conditions requiring hospitalization are associated with a higher incidence of myocardial infarction compared to those with mild conditions treated at home (RR 8.00).

The outcome of COPD patients with AMI varies widely, depending on the patient’s clinical symptoms and the delay in identifying the condition. Atypical clinical manifestations related to the size and location of the infarction due to the delay in therapy might confuse the diagnosis and treatment of AMI. Delays in giving treatment, such as reperfusion in STEMI patients, can cause heart failure and possibly death.

**LIMITATIONS**

In our case, the causes of myocardial infarction are unclear. The abnormalities in the heart and blood vessels cannot be identified since further investigations have not yet been conducted. Sepsis also cannot be ignored, where the cardiovascular system is affected. In sepsis condition, cardiovascular dysfunction occurs through a complex mechanism. The ejection fraction of both ventricles dropped due to inadequate preload, suppression of myocardial contractility, and reduced ventricular compliance. Depression in cardiac function can cause cardio-toxic inflammatory mediators (IL-1, TNF-α, and nitric oxide). So, an increase in heart rate will be found to compensate for and maintain the cardiac output. Circulating chemicals (sepsis-induced), vasopressors, and catecholamine toxicity
may also potentially mediate cTn increases in addition to T1MI or T2MI.\(^7\)

**CONCLUSION**

Physicians should look for general and comprehensive reasons why the patient's condition worsens. The ECG and cardiac enzymes, like symptoms, vital signs, clinical findings, and other changes, must be closely monitored. So, physicians will not miss cases of acute myocardial infarction in AECOPD patients, and the prognosis will improve.

**ACKNOWLEDGMENTS**

None.

**CONFLICT OF INTEREST**

None.

**FUNDING**

None.

**DISCLOSURE**

The scientific poster of this case report was presented at the 9th Pulmonary Update 2023.

**REFERENCES**


